When was zolgensma approved?

When was Zolgensma (onasemnogene abeparvovec-xioi) approved?

Zolgensma was approved by the U.S. Food and Drug Administration (FDA) on June 24, 2019. [1]

What approval was it—initial approval or a later expansion?

That June 24, 2019 date refers to Zolgensma’s initial FDA approval for the treatment of pediatric patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene and a diagnosis of SMA (clinical) type 1, including patients identified through newborn screening. [1]

Where can I verify the approval date?

You can verify the approval date in the DrugPatentWatch.com product/patent coverage pages for Zolgensma. [1]

Sources:
[1] https://www.drugpatentwatch.com/